composto, composição, e, método de tratamento de distúrbio hiperproliferativo

Compounds represented by Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least two of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3beta, EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, IGF-1R, Ron, Ret, and KDR kinases in ani...

Full description

Saved in:
Bibliographic Details
Main Authors GRAHAM DAWSON, SHAZIA SADIQ, LIFU MA, OSCAR BARBA, SALEH AHMED, IMAAD SABA, MATTHEW COX, NEIL ANTHONY PEGG, HANQING DONG, PAULA TAVARES, BIJOY PANICKER, COLIN PETER SAMBROOK SMITH, WILLIAM GATTRELL, AN-HU LI, JOHN KITCHIN, ARNO G. STEINIG, ROBIN WILKES, KATHRYN STOLZ, QINGHUA FELIX WENG, KENNETH FOREMAN, JASON BLOXHAM, DON SMYTH
Format Patent
LanguagePortuguese
Published 27.05.2008
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:Compounds represented by Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least two of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3beta, EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, IGF-1R, Ron, Ret, and KDR kinases in animals, including humans, for the treatment and/or prevention of various diseases and conditions such as cancer.
Bibliography:Application Number: BR2005PI14094